Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.44 |
| ▸ | FURIN | P09958 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31558981 | 0.91 | PTPN1 (0.47) | CASP3TLR2PTPN1 | |
| SCHEMBL18429578 | 0.90 | KMT2A (0.52) | CASP3TLR2KMT2APTPN1FURIN | |
| SCHEMBL31047755 | 0.90 | CASP3 (0.49) | CASP3TLR2KMT2APTPN1FURIN | |
| SCHEMBL35210479 | 0.90 | CASP3 (0.49) | CASP3TLR2KMT2APTPN1FURIN | |
| SCHEMBL3193169 | 0.88 | CASP3 (0.55) | CASP3TLR2KMT2A | |
| SCHEMBL13401540 | 0.88 | CASP3 (0.55) | CASP3TLR2KMT2A | |
| SCHEMBL29702562 | 0.88 | CASP3 (0.55) | CASP3TLR2KMT2A | |
| SCHEMBL13830553 | 0.88 | CASP3 (0.55) | CASP3TLR2KMT2A | |
| SCHEMBL31045201 | 0.88 | CASP3 (0.55) | CASP3TLR2KMT2A | |
| SCHEMBL29580018 | 0.88 | CASP3 (0.55) | CASP3TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20250135026-A1 | Antibody Drug Conjugates | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-01 | — | — | US | disclosed |
| WO-2023125530-A1 | ANTIBODY DRUG CONJUGATES | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | SLC3A2, SLC7A1, SLC43A1 | CASP3 3565/4885TLR2 926/4885KMT2A 2789/4885 |
| US-20250135026-A1 | Antibody Drug Conjugates | CD22, FCGR2A, FCGR3B | CASP3 4072/4885TLR2 3334/4885KMT2A 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.